Table 2

Axial and Peripheral involvement based on HLA-B*27 status with details of subtypes of SpA captured

Total
N=2269
HLA-B*27+
N=1753
HLA-B*27–
N=516
P value
Axial involvement2211 (97.4%)1707 (97.4%)504 (97.7%)0.706
Any peripheral manifestation1507 (66.4%)1138 (65.0%)369 (71.5%)0.006

  • Axial SpA

  • pSpA

  • PsA

  • ReA+IBD

  • JuvSpA+others

1907 (84.0%)
149 (6.6%)
124 (5.5%)
43 (1.9%)
46 (2.0%)
1541 (87.9%)
111 (6.3%)
56 (3.2%)
16 (0.9%)
29 (1.7%)
366 (70.9%)
38 (7.4%)
68 (13.2%)
27 (5.2%)
17 (3.3%)
<0.001
  • axSpA, Axial spondyloarthritis; bDMARDs, biological disease-modifying anti-rheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; JuvSpA, juveline spondyloarthritis; PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; REA, reactive arthritis.